Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Notch signalling promotes differentiation of epidermal cells and acts as a tumour suppressor in the skin by interacting with various pathways and mechanisms.

This study found that patients with scarring alopecia have higher rates of various systemic conditions, such as vitamin D deficiency and metabolic syndrome, compared to the national averages, and noted a significant association between certain types of scarring alopecia and atherosclerotic cardiovascular disease.

This study found that applying a combination of pyridine‐2, 4‐dicarboxylic acid diethyl ester and resveratrol significantly increased hair density in Caucasian women after 1.5 months, potentially due to their synergistic effect on the HIF‐1α pathway.

This study found that age-related hair thinning in Caucasian women over 50 involves significant structural changes within the hair follicle, suggesting an "aged hair program" rather than just producing thinner hairs.

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

In this study, the disruption of Gh/tissue transglutaminase in mice did not affect viability but reduced thymocyte viability and fibroblast adhesion, suggesting its role in cell stabilization and extracellular matrix interactions.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This study found that VDR knockout mice exhibited muscle and motor impairments affecting locomotor behavior, while cognitive functions such as exploration, working memory, and anxiety appeared unaffected.

This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

In this study, researchers found that in late pregnancy, the neuroactive progesterone metabolite allopregnanolone inhibits HPA axis responses to immune challenges via an opioid-mediated mechanism.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

In this study, newly diagnosed women with mycosis fungoides or Sézary syndrome and those with alopecia experienced significantly poorer health-related quality of life.

In this study, the researchers found that treatment with the JAK inhibitor tofacitinib in alopecia areata patients may reduce clonal CD8+ T cell expansions but does not eliminate them entirely, which could contribute to disease relapse.

This study suggests that Myc superfamily transcription factors may have distinct roles in different epithelial compartments of the human hair follicle, possibly influencing cell fate in the putative stem cell compartment.

This study identified at least eight genetic regions associated with alopecia areata, which may lead to the development of new targeted therapies based on these findings.

This study found that ICAM-1 expression in murine skin is developmentally regulated and crucial for skin and hair follicle remodeling beyond its recognized role in immune responses.

This study suggests that the presence and arrangement of plasmacytoid dendritic cells can help distinguish chronic cutaneous lupus erythematosus from other types of scarring alopecia.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

In this study, tofacitinib treatment led to significant hair regrowth in 60% of patients with moderate-to-severe alopecia areata, suggesting potential for JAK inhibitors in treating this condition.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

Abatacept may help some people with alopecia areata regrow hair.

This study showed that spironolactone effectively reduces morbidity and mortality in moderate to severe heart failure with reduced ejection fraction, but its benefits in heart failure with preserved ejection fraction are less clear.

This study identified the Arabidopsis cation chloride cotransporter CCC1 as essential for regulating pH and function in the trans-Golgi network/early endosome, with its absence causing significant growth and stress response defects.

This overview details the Dermatologic Surgery journal's comprehensive focus on cosmetic and reconstructive skin surgery, but it presents no new research findings.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This paper discusses the role of the National Alopecia Areata Foundation in advancing research on alopecia areata, emphasizing genetic and immunological factors, and reports no new clinical findings.